NASDAQ · PBLS
Parabilis Medicines, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for PBLS: Nov 12, 2026
Parabilis Medicines, Inc. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.4.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.40 | $-0.35 | $-0.45 | 2 |
| Dec 2026 | $-0.36 | $-0.36 | $-0.36 | 1 |
| Mar 2027 | $-0.37 | $-0.37 | $-0.37 | 1 |
| Jun 2027 | $-0.38 | $-0.38 | $-0.38 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · MarketBeat · Nasdaq Newsroom · The Motley Fool- RTTNews · Oct 26, 8:03 AM EDTParabilis Medicines Reports 72% Response Rate For Zolucatetide In Desmoid Tumors; Stock Down(RTTNews) – Parabilis Medicines, Inc. (PBLS) announced updated Phase 1/2 data showing that its investigational drug zolucatetide demonstrated encouraging efficacy and a favorable safety and tolerability profile in patients with desmoid tumors. The results were presented in an ora
- MarketBeat · Oct 24, 5:02 PM EDTParabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027Parabilis Medicines (NASDAQ:PBLS) presented updated interim phase I/II data for investigational beta-catenin/TCF inhibitor zolucatetide in desmoid tumors at the European Society for Medical Oncology Congress in Madrid, reporting tumor responses, disease control and an FDA-aligned
- RTTNews · Oct 14, 5:08 PM EDTParabilis Begins Dose-Ranging Study For Zolucatetide In Treating FAP; Data By Q1 '27(RTTNews) – Parabilis Medicines Inc. (PBLS), a clinical-stage biopharmaceutical company, on Wednesday reported the initiation of the dose-ranging clinical study of Zolucatetide in treating familial adenomatous polyposis. Familial adenomatous polyposis (FAP) is a genetic diseas
- RTTNews · Sep 18, 4:36 AM EDTBiotech Stocks At 52-Week Highs – MNOV +36%, PBLS +10%, ABCL +9%, HAE, NEO(RTTNews) – The following biotech stocks reached a 52-week high on September 17, 2026, driven by the gain on certain clinical or financial results.
- RTTNews · Aug 26, 6:28 AM EDTParabilis Medicines Names Former J&J Oncology Executive Craig Tendler To Board(RTTNews) – Parabilis Medicines (PBLS), a clinical-stage biopharmaceutical company, announced the appointment of Craig L. Tendler, M.D., to its Board of Directors.He has served as a scientific advisor to Parabilis Medicines, a role he will continue alongside his Board responsibil
- RTTNews · Aug 18, 7:03 AM EDTBiotech Stocks At 52-Week Highs – OABI, IOVA, PBLS, RVMD, BLFS(RTTNews) – The following biotech stocks reached a 52-week high on August 17, 2026, driven by key catalysts including prospective clinical trial results and announced acquisitions.
- RTTNews · Aug 5, 4:09 AM EDTBiotech Stocks At 52-Week Highs – UFPT +25%, INFU +33%, SOPH +20% On Q2 Reports, REPL, PBLS(RTTNews) – The following biotech stocks reached a 52-week high on August 4, 2026, driven by key catalysts like positive quarterly results or certain regulatory milestones.
- Nasdaq Newsroom · Jul 1, 8:30 AM EDTNasdaq Listings Delivers Record-Breaking First HalfNasdaq’s first half of 2026 was the strongest in U.S. exchange history; the company oversaw a record-breaking $129.3 billion raised from new listings, led by SpaceX.
- The Motley Fool · Jun 27, 8:20 PM EDTThis Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX — and Regeneron Is Already InvestedParabilis saw its shares rise by more than SpaceX's shares did after its IPO.
- The Motley Fool · Jun 20, 1:01 PM EDTFresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy?Director Alan Sebulsky acquired 17,500 shares for $474,000, based on a weighted average purchase price of $27.06 per share.
- BNK Invest · Jun 18, 1:36 PM EDTThursday 6/18 Insider Buying Report: PBLS, ABTCAs the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy — they expect to make money. So let's look at two noteworthy recent insider buys. On Monday, Parabilis Medicines', Alan Sebulsky, made a $473,529 buy of PBLS, purch
- The Motley Fool · Jun 15, 4:22 AM EDTSpaceX Climbed Nearly 20% in Its First Day of Trading. Here's Where the Stock Price Will Be in 3 Months, According to History.SpaceX rose $75 billion last week in the world’s biggest-ever IPO.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Parabilis Medicines, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.